You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
宜明昂科-B(01541.HK)已從Instil收取1000萬美元的里程碑付款

格隆匯7月30日丨宜明昂科-B(01541.HK)公告,於IMM2510/AXN-2510獲FDA批準於美國展開I期臨牀試驗後,公司已從Instil收取10百萬美元的里程碑付款。截至本公告日期,根據授權及合作協議收取的付款總額已達30百萬美元(包括里程碑付款),顯示公司與Instil之間的持續進展及堅定承諾。

IMM2510/AXN-2510是一種PD-L1和VEGF的雙特異性抗體,目前正開發用於治療多種實體腫瘤癌症。IMM2510/AXN-2510與其他PD-(L)1xVEGF雙特異性抗體的差異在於其VEGF阻斷,可結合血管內皮生長因子A(VEGF-A)以外的多種VEGF受體配體;雙特異性結構可利用PD-L1作爲腫瘤微環境(TME)中的錨點;以及增強的抗體依賴性細胞毒性(ADCC),可直接殺死PD-L1陽性的腫瘤細胞。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account